Sandbox:Roukoz: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 8: | Line 8: | ||
{{familytree | | | | |D01| | | | D02| | | | D03 |D01='''Squamous cell carcinoma'''|D02='''Neuroendocrine carcinoma'''|D03='''Adenocarcinoma and poorly differntiated carcinoma'''}} | {{familytree | | | | |D01| | | | D02| | | | D03 |D01='''Squamous cell carcinoma'''|D02='''Neuroendocrine carcinoma'''|D03='''Adenocarcinoma and poorly differntiated carcinoma'''}} | ||
{{familytree | | | | | |!| | | | | |!| | | | | |!| | | | }} | {{familytree | | | | | |!| | | | | |!| | | | | |!| | | | }} | ||
{{familytree | | | | | |!| | | | |boxstyle=text-align: left;|E01| | | | |!| |E01=• Octreoscan<br> • Plasma chromogranin A}} | {{familytree | | | | | |!| | | | |boxstyle=text-align: left;|E01| | | | |!| |E01=• Octreoscan<br>• Plasma chromogranin A}} | ||
{{familytree | | | | |F01| | | | | | | | | | F02 | |F01=Additional tests specific to location of metastasis|F02=Gender specific tests}} | {{familytree | | | | |F01| | | | | | | | | | F02 | |F01=Additional tests specific to location of metastasis|F02=Gender specific tests}} | ||
{{familytree | | | | | |!| | | | | | | | | | | |!|| | }} | {{familytree | | | | | |!| | | | | | | | | | | |!|| | }} | ||
Line 21: | Line 21: | ||
{{familytree | J01 | | J02 | | J03 | | J04 | | J05 | | J06 | | J07 | | J08 | | J09 |J01=Midline and/or mediastinal lymphadenopathy|J02=Cervical and/or supraclavicular lymphadenopathy|J03=Axillary lymphadenopathy|J04=Liver metastasis|J05=Lung metastasis|J06=Bone metastasis|J07=Single metastasis|J08=Pleural effusion|J09=Periotneal effusion}} | {{familytree | J01 | | J02 | | J03 | | J04 | | J05 | | J06 | | J07 | | J08 | | J09 |J01=Midline and/or mediastinal lymphadenopathy|J02=Cervical and/or supraclavicular lymphadenopathy|J03=Axillary lymphadenopathy|J04=Liver metastasis|J05=Lung metastasis|J06=Bone metastasis|J07=Single metastasis|J08=Pleural effusion|J09=Periotneal effusion}} | ||
{{familytree | |!| | | |!| | | |!| | | |!| | | |!| | | |!| | | |!| | | |!| | | |!| |}} | {{familytree | |!| | | |!| | | |!| | | |!| | | |!| | | |!| | | |!| | | |!| | | |!| |}} | ||
{{familytree |boxstyle=text-align: left;| K01 | | K02 | | K03 | | K04 | | K05 | | K06 | | K07 | | K08 | | K09 |K01=• Testicular ultrasound<br>• Chest and abdominal CT scan|K02=• Testicular ultrasound<br>• Head and neck CT scan<br>• Panendoscopy<br>• EBV testing (to rule out undifferentiated nasopharyngeal carcinoma)|K03=Women:<br>• Breast ultrasound<br>• Breast MRI|K04=Women:<br>• aFP assay (if undifferntiated carcinoma)<br>• Colposcopy|K05=Women:<br>• BHCG<br>Men:<br>• Testicular ultrasound<br>• Chest and abdominal CT scan|K06=• Bone scintigraphy<br>• Xrays of painful areas|K07=• Full body CT scan<br>• Bone scintigraphy|K08=• Chest CT scan|K09=Women:<br>• Abdominal and pelvic CT scan}} | |||
{{familytree/end}} | {{familytree/end}} |
Revision as of 21:36, 10 October 2018
Tumor of unknown primary origin | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
• Full medical history and physical exam • Basic blood and bichemical analysis • CT scan of chest, abdomen, and pelvis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Histopathologic examination | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Squamous cell carcinoma | Neuroendocrine carcinoma | Adenocarcinoma and poorly differntiated carcinoma | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
• Octreoscan • Plasma chromogranin A | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Additional tests specific to location of metastasis | Gender specific tests | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cervical lymphadenopathy | Inguinal lymphadenopathy | Bone metastasis | Male | Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
• Panendoscopy • CT scan of head and neck • Diagnostic bilateral amygdalectomy | • Complete clinical examination of external genital organs • Pelvic CT scan or ultrasound | • Anoscopy • Colposcopy (if female) • Complete clinical examination of head and neck • Panendoscopy • Bone scintigraphy • Xrays of painful areas | • PSA • aFP • BHCG | • Mammography • Pelvic ultrasound or CT scan | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Additional tests specific to location of metastasis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Midline and/or mediastinal lymphadenopathy | Cervical and/or supraclavicular lymphadenopathy | Axillary lymphadenopathy | Liver metastasis | Lung metastasis | Bone metastasis | Single metastasis | Pleural effusion | Periotneal effusion | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
• Testicular ultrasound • Chest and abdominal CT scan | • Testicular ultrasound • Head and neck CT scan • Panendoscopy • EBV testing (to rule out undifferentiated nasopharyngeal carcinoma) | Women: • Breast ultrasound • Breast MRI | Women: • aFP assay (if undifferntiated carcinoma) • Colposcopy | Women: • BHCG Men: • Testicular ultrasound • Chest and abdominal CT scan | • Bone scintigraphy • Xrays of painful areas | • Full body CT scan • Bone scintigraphy | • Chest CT scan | Women: • Abdominal and pelvic CT scan | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||